We are interested in conducting research leveraging UK Biobank in TED, MG, NMOSD, IgG4-RD, pulmonary fibrosis, systemic sclerosis, cutaneous lupus erythematosus, ANCA-associated vasculitis, Sjögren’s syndrome, and uncontrolled gout to characterize the natural history and burden of disease. Using validated and peer-reviewed approaches, we will define subgroups of patients with existing disease. The specifically defined patient groups will allow further research in better understanding unmet need, patient journeys, and disease progression.
Our aim is to better characterise the distribution of known and emerging diseases, characterise unmet medical need, estimate the number of patients who could potentially benefit from novel therapies, estimate disease burden and its progression by assessing the rate of initial and subsequent events, describe treatment journey and long term clinical outcomes, and develop and/or replicate predictive models for identifying patients of high-risk or those more likely to receive outside benefit of therapies using phenotypical, imaging, metabolomic, and/or genomics data. Findings from these analyses may translate into better treatment outcomes and clinical care of patients. By advancing the knowledge of rare disease and inflammatory disease like TED, MG, NMOSD, IgG4-RD, pulmonary fibrosis, systemic sclerosis, cutaneous lupus erythematosus, ANCA-associated vasculitis, Sjögren’s syndrome, and uncontrolled gout, this research project will help inform researchers, clinicians, and patients and positively impact public health.
